A government alert has been sent to private weight-loss clinics instructing them to stop prescribing slimming injections as “very limited, intermittent supplies” are putting the lives of diabetes patients in danger.
The national patient safety alert was sent to both NHS and private healthcare providers by the Department of Health and Social Care, warning of shortages to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - including semaglutide (Ozempic), dulaglutide, liraglutide and exenatide - which are used to treat diabetes.
